OBJECTIVE:Trimethoprim-sulfamethoxazole prophylaxis is recommended for HIV-exposed infants until breastfeeding ends and HIV infection has been excluded. Extending prophylaxis with a focus on preventing malaria may be beneficial in high transmission areas. We investigated three regimens for the prevention of malaria in young HIV-exposed children. DESIGN: An open-label, randomized controlled trial. SETTING: Tororo, Uganda, a rural area with intense, year-round, malaria transmission. PARTICIPANTS: Two hundred infants aged 4-5 months enrolled and 186 randomized after cessation of breastfeeding and confirmed to be HIV uninfected (median 10 months of age). INTERVENTION: No chemoprevention, monthly sulfadoxine-pyrimethamine, daily trimethoprim-sulfamethoxazole or monthly dihydroartemisinin-piperaquine given from randomization to 24 months of age. MAIN OUTCOME MEASURES: The primary outcome was the incidence of malaria during the intervention period. Secondary outcomes included the incidence of hospitalization, diarrhoeal illness, or respiratory tract infection; prevalence of anaemia and asymptomatic parasitemia; measures of safety; and incidence of malaria over 1 year after the intervention was stopped. RESULTS: During the intervention, the incidence of malaria in the no chemoprevention group was 6.28 episodes per person-year at risk. Protective efficacy was 69% [95% confidence interval (95% CI) 53-80, P < 0.001] for dihydroartemisinin-piperaquine, 49% (95% CI 23-66, P = 0.001) for trimethoprim-sulfamethoxazole and 9% for sulfadoxine-pyrimethamine (95% CI -35 to 38, P = 0.65). There were no significant differences in any secondary outcomes, with the exception of a lower prevalence of asymptomatic parasitemia in the dihydroartemisinin-piperaquine arm. CONCLUSION: Monthly chemoprevention with dihydroartemisinin-piperaquine was well tolerated and associated with a significant reduction in malaria in young HIV-exposed children.
RCT Entities:
OBJECTIVE:Trimethoprim-sulfamethoxazole prophylaxis is recommended for HIV-exposed infants until breastfeeding ends and HIV infection has been excluded. Extending prophylaxis with a focus on preventing malaria may be beneficial in high transmission areas. We investigated three regimens for the prevention of malaria in young HIV-exposed children. DESIGN: An open-label, randomized controlled trial. SETTING: Tororo, Uganda, a rural area with intense, year-round, malaria transmission. PARTICIPANTS: Two hundred infants aged 4-5 months enrolled and 186 randomized after cessation of breastfeeding and confirmed to be HIV uninfected (median 10 months of age). INTERVENTION: No chemoprevention, monthly sulfadoxine-pyrimethamine, daily trimethoprim-sulfamethoxazole or monthly dihydroartemisinin-piperaquine given from randomization to 24 months of age. MAIN OUTCOME MEASURES: The primary outcome was the incidence of malaria during the intervention period. Secondary outcomes included the incidence of hospitalization, diarrhoeal illness, or respiratory tract infection; prevalence of anaemia and asymptomatic parasitemia; measures of safety; and incidence of malaria over 1 year after the intervention was stopped. RESULTS: During the intervention, the incidence of malaria in the no chemoprevention group was 6.28 episodes per person-year at risk. Protective efficacy was 69% [95% confidence interval (95% CI) 53-80, P < 0.001] for dihydroartemisinin-piperaquine, 49% (95% CI 23-66, P = 0.001) for trimethoprim-sulfamethoxazole and 9% for sulfadoxine-pyrimethamine (95% CI -35 to 38, P = 0.65). There were no significant differences in any secondary outcomes, with the exception of a lower prevalence of asymptomatic parasitemia in the dihydroartemisinin-piperaquine arm. CONCLUSION: Monthly chemoprevention with dihydroartemisinin-piperaquine was well tolerated and associated with a significant reduction in malaria in young HIV-exposed children.
Authors: Jonathan Mermin; John Paul Ekwaru; Cheryl A Liechty; Willy Were; Robert Downing; Ray Ransom; Paul Weidle; John Lule; Alex Coutinho; Peter Solberg Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: James D Campbell; David Moore; Richard Degerman; Frank Kaharuza; Willy Were; Emmy Muramuzi; George Odongo; Milton Wetaka; Jonathan Mermin; Jordan W Tappero Journal: Clin Infect Dis Date: 2012-03-14 Impact factor: 9.079
Authors: Anna Dow; Dumbani Kayira; Michael Hudgens; Annelies Van Rie; Caroline C King; Sascha Ellington; Athena Kourtis; Abigail Norris Turner; Steven Meshnick; Zebrone Kacheche; Denise J Jamieson; Charles Chasela; Charles van der Horst Journal: Pediatr Infect Dis J Date: 2012-08 Impact factor: 2.129
Authors: Mahamadou A Thera; Paul S Sehdev; Drissa Coulibaly; Karim Traore; Mamane N Garba; Yacouba Cissoko; Abdoulaye Kone; Ando Guindo; Alassane Dicko; Abdoul H Beavogui; Abdoulaye A Djimde; Kirsten E Lyke; Dapa A Diallo; Ogobara K Doumbo; Christopher V Plowe Journal: J Infect Dis Date: 2005-10-13 Impact factor: 5.226
Authors: Athena P Kourtis; Jeffrey Wiener; Dumbani Kayira; Charles Chasela; Sascha R Ellington; Lisa Hyde; Mina Hosseinipour; Charles van der Horst; Denise J Jamieson Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh Journal: J Infect Dis Date: 2013-02-27 Impact factor: 5.226
Authors: Megan Landes; Monique van Lettow; Adrienne K Chan; Isabell Mayuni; Erik J Schouten; Richard A Bedell Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Victor Bigira; James Kapisi; Tamara D Clark; Stephen Kinara; Florence Mwangwa; Mary K Muhindo; Beth Osterbauer; Francesca T Aweeka; Liusheng Huang; Jane Achan; Diane V Havlir; Philip J Rosenthal; Moses R Kamya; Grant Dorsey Journal: PLoS Med Date: 2014-08-05 Impact factor: 11.069
Authors: Nicole L Davis; Eric J Barnett; William C Miller; Anna Dow; Charles S Chasela; Michael G Hudgens; Dumbani Kayira; Gerald Tegha; Sascha R Ellington; Athena P Kourtis; Charles van der Horst; Denise J Jamieson; Jonathan J Juliano Journal: Clin Infect Dis Date: 2015-04-21 Impact factor: 9.079
Authors: Ronak Chhaya; Jonathan Weiss; Victoria Seffren; Alla Sikorskii; Paula M Winke; Julius C Ojuka; Michael J Boivin Journal: Child Neuropsychol Date: 2017-05-22 Impact factor: 2.500
Authors: Paul Natureeba; Abel Kakuru; Mary Muhindo; Teddy Ochieng; John Ategeka; Catherine A Koss; Albert Plenty; Edwin D Charlebois; Tamara D Clark; Bridget Nzarubara; Miriam Nakalembe; Deborah Cohan; Gabrielle Rizzuto; Atis Muehlenbachs; Theodore Ruel; Prasanna Jagannathan; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: J Infect Dis Date: 2017-07-01 Impact factor: 5.226
Authors: Michael J Boivin; Jonathan Weiss; Ronak Chhaya; Victoria Seffren; Jorem Awadu; Alla Sikorskii; Bruno Giordani Journal: Neuropsychology Date: 2017-05-25 Impact factor: 3.295
Authors: Mary K Muhindo; Prasanna Jagannathan; Abel Kakuru; Bishop Opira; Peter Olwoch; Jaffer Okiring; Noeline Nalugo; Tamara D Clark; Theodore Ruel; Edwin Charlebois; Margaret E Feeney; Diane V Havlir; Grant Dorsey; Moses R Kamya Journal: Lancet Infect Dis Date: 2019-07-12 Impact factor: 25.071
Authors: Michael J Boivin; Noeline Nakasujja; Itziar Familiar-Lopez; Sarah M Murray; Alla Sikorskii; Jorem Awadu; Cilly Shohet; Deborah Givon; Horacio Ruiseñor-Escudero; Elizabeth E Schut; Robert O Opoka; Judith K Bass Journal: J Dev Behav Pediatr Date: 2017 Nov/Dec Impact factor: 2.225